A Phase 3 interventional study of Evolocumab and Placebo in Hypercholesterolemia, sponsored by Amgen. Completed at 226 sites in 32 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-02-20.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 7th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 14th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 970 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 14th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery disease taking lipid lowering therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet the following criteria at the qualifying coronary catheterization procedure:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
Drug: Placebo
Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha®
Administered by subcutaneous injection
Change From Baseline in Percent Atheroma Volume at Week 78
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma.
Time frame: Baseline and week 78
Change From Baseline in Total Atheroma Volume at Week 78
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants.
Time frame: Baseline and week 78
Percentage of Participants With Regression in Percent Atheroma Volume
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma. Regression in PAV was defined as any reduction from baseline in PAV.
Time frame: Baseline and week 78
Percentage of Participants With Regression in Total Atheroma Volume
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants. Regression in TAV was defined as any reduction from baseline in TAV.
Time frame: Baseline and week 78
This study was conducted at 163 centers in 30 countries in Europe, North America, Asia Pacific, and Latin America. The first participant was enrolled on 18 April 2013 and the last participant enrolled on 12 January 2015.
| Milestone | Placebo | Evolocumab |
|---|---|---|
| Started | 486 | 484 |
| Received treatment | 484 | 484 |
| Completed | 466 | 468 |
| Not completed | 20 | 16 |
| Withdrew: Withdrawal by subject | 14 | 8 |
| Withdrew: Death | 2 | 3 |
| Withdrew: Sponsor decision | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 4 |
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma.
| percent atheroma volume | Placebo | Evolocumab |
|---|---|---|
| Change From Baseline in Percent Atheroma Volume at Week 78 | 0.053 ± 0.189 | -0.955 ± 0.190 |
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants.
| mm³ | Placebo | Evolocumab |
|---|---|---|
| Change From Baseline in Total Atheroma Volume at Week 78 | -0.910 ± 1.214 | -5.799 ± 1.216 |
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma. Regression in PAV was defined as any reduction from baseline in PAV.
| percentage of participants | Placebo | Evolocumab |
|---|---|---|
| Percentage of Participants With Regression in Percent Atheroma Volume | 47.3 (42.6 to 52.0) | 64.3 (59.6 to 68.7) |
Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants. Regression in TAV was defined as any reduction from baseline in TAV.
| percentage of participants | Placebo | Evolocumab |
|---|---|---|
| Percentage of Participants With Regression in Total Atheroma Volume | 48.9 (44.2 to 53.7) | 61.5 (56.7 to 66.0) |
Collected over From first dose of study drug until week 80. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 142/484 (29.3%) | 120/484 (24.8%) |
| Evolocumab | — | 135/484 (27.9%) | 114/484 (23.6%) |
| Event | Placebo | Evolocumab |
|---|---|---|
| Angina pectorisCardiac disorders | 11/484 | 17/484 |
| Coronary artery diseaseCardiac disorders | 13/484 | 7/484 |
| Non-cardiac chest painGeneral disorders | 6/484 | 11/484 |
| Angina unstableCardiac disorders | 7/484 | 8/484 |
| Acute myocardial infarctionCardiac disorders | 5/484 | 6/484 |
| Atrial fibrillationCardiac disorders | 4/484 | 6/484 |
| Arteriosclerosis coronary arteryCardiac disorders | 5/484 | 0/484 |
| Coronary artery stenosisCardiac disorders | 5/484 | 3/484 |
| PneumoniaInfections and infestations | 5/484 | 0/484 |
| Myocardial infarctionCardiac disorders | 4/484 | 0/484 |
| Event | Placebo | Evolocumab |
|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 27/484 | 34/484 |
| HypertensionVascular disorders | 34/484 | 29/484 |
| Chest painGeneral disorders | 26/484 | 33/484 |
| Angina pectorisCardiac disorders | 32/484 | 21/484 |
| HeadacheNervous system disorders | 29/484 | 19/484 |
| Age, Continuous(years) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 59.8 ± 8.8 | 59.8 ± 9.6 | 59.8 ± 9.2 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Female | 135 | 135 | 270 |
| Male | 351 | 349 | 700 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Hispanic or Latino | 24 | 34 | 58 |
| Not Hispanic or Latino | 462 | 450 | 912 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 17 | 14 | 31 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 5 | 4 | 9 |
| White | 453 | 456 | 909 |
| Multiple | 6 | 7 | 13 |
| Other | 3 | 2 | 5 |
| Stratification Factor: Geographical Region(participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| North America | 88 | 86 | 174 |
| Europe | 332 | 332 | 664 |
| Latin America | 16 | 15 | 31 |
| Asia Pacific | 50 | 51 | 101 |
Showing the first 100 of 226 sites across 32 countries. Choose a country and city above to see the rest.
Ran from Apr 2013 to primary completion in Jul 2016, 38 months.
Results were first posted in Jan 2018, 1 year 5 months after primary completion. A results delay was requested in Jun 2017.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 38 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab